Oncolytics Biotech Inc. (ONC.TO)
CAD 1.1
(-2.65%)
CAD 1.1
(-2.65%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -403 Thousand CAD | -2.81% |
| 2022 | -392 Thousand CAD | 13.29% |
| 2021 | -452.06 Thousand CAD | -1.32% |
| 2020 | -446.18 Thousand CAD | 8.11% |
| 2019 | -485.57 Thousand CAD | -409.12% |
| 2018 | -95.37 Thousand CAD | -5.08% |
| 2017 | -90.76 Thousand CAD | 44.05% |
| 2016 | -162.23 Thousand CAD | 10.08% |
| 2015 | -180.41 Thousand CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 100.0% |
| 2011 | -5.33 Million CAD | -27.3% |
| 2010 | -4.19 Million CAD | -10.78% |
| 2009 | -3.78 Million CAD | 12.27% |
| 2008 | -4.31 Million CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | -100.0% |
| 2005 | 783.45 Thousand CAD | 11.96% |
| 2004 | 699.75 Thousand CAD | 123.35% |
| 2003 | 313.3 Thousand CAD | 50.0% |
| 2002 | 208.86 Thousand CAD | 0.0% |
| 2001 | - CAD | -100.0% |
| 2000 | 310 Thousand CAD | 30999900.0% |
| 1999 | 1.00 CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -98 Thousand CAD | 20.33% |
| 2024 Q1 | -123 Thousand CAD | -14.95% |
| 2023 FY | -403 Thousand CAD | -2.81% |
| 2023 Q1 | -97 Thousand CAD | 2.03% |
| 2023 Q2 | -96 Thousand CAD | 1.03% |
| 2023 Q4 | -107 Thousand CAD | -3.88% |
| 2023 Q3 | -103 Thousand CAD | -7.29% |
| 2022 Q4 | -99.01 Thousand CAD | -1.22% |
| 2022 Q3 | -97.81 Thousand CAD | -0.22% |
| 2022 FY | -392 Thousand CAD | 13.29% |
| 2022 Q1 | -97.56 Thousand CAD | -0.61% |
| 2022 Q2 | -97.6 Thousand CAD | -0.04% |
| 2021 Q1 | -106.73 Thousand CAD | 0.0% |
| 2021 FY | -452.06 Thousand CAD | -1.32% |
| 2021 Q4 | -96.97 Thousand CAD | -14.73% |
| 2021 Q3 | -84.52 Thousand CAD | 48.41% |
| 2021 Q2 | -163.83 Thousand CAD | -53.5% |
| 2020 FY | -446.18 Thousand CAD | 8.11% |
| 2020 Q4 | - CAD | 0.0% |
| 2020 Q3 | - CAD | 0.0% |
| 2020 Q2 | - CAD | 0.0% |
| 2020 Q1 | - CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2019 FY | -485.57 Thousand CAD | -409.12% |
| 2019 Q4 | - CAD | 0.0% |
| 2019 Q3 | - CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 FY | -95.37 Thousand CAD | -5.08% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2017 FY | -90.76 Thousand CAD | 44.05% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 FY | -162.23 Thousand CAD | 10.08% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 FY | -180.41 Thousand CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 100.0% |
| 2012 Q1 | - CAD | 100.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 FY | - CAD | 100.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q4 | -4.85 Million CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 FY | -5.33 Million CAD | -27.3% |
| 2011 Q1 | - CAD | 100.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q4 | -5.33 Million CAD | 0.0% |
| 2010 Q4 | -4.19 Million CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 FY | -4.19 Million CAD | -10.78% |
| 2010 Q1 | - CAD | 100.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 FY | -3.78 Million CAD | 12.27% |
| 2009 Q1 | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q4 | -3.78 Million CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 FY | -4.31 Million CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 100.0% |
| 2007 FY | - CAD | 0.0% |
| 2007 Q4 | - CAD | -100.0% |
| 2007 Q3 | 319.22 Thousand CAD | 0.0% |
| 2007 Q1 | -906.71 Thousand CAD | 0.0% |
| 2006 FY | - CAD | -100.0% |
| 2006 Q3 | 320.45 Thousand CAD | -4.25% |
| 2006 Q2 | 334.68 Thousand CAD | 140.53% |
| 2006 Q4 | - CAD | -100.0% |
| 2006 Q1 | -825.71 Thousand CAD | -1495.64% |
| 2005 Q1 | 244.65 Thousand CAD | 19.38% |
| 2005 Q2 | 167.97 Thousand CAD | -31.34% |
| 2005 FY | 783.45 Thousand CAD | 11.96% |
| 2005 Q3 | 245.03 Thousand CAD | 45.88% |
| 2005 Q4 | 59.16 Thousand CAD | -75.86% |
| 2004 Q1 | 117.35 Thousand CAD | -7.37% |
| 2004 Q4 | 204.94 Thousand CAD | 5.64% |
| 2004 Q2 | 183.46 Thousand CAD | 56.33% |
| 2004 Q3 | 194 Thousand CAD | 5.75% |
| 2004 FY | 699.75 Thousand CAD | 123.35% |
| 2003 Q1 | 43.17 Thousand CAD | -2.88% |
| 2003 FY | 313.3 Thousand CAD | 50.0% |
| 2003 Q4 | 126.69 Thousand CAD | 24.11% |
| 2003 Q3 | 102.08 Thousand CAD | 146.84% |
| 2003 Q2 | 41.35 Thousand CAD | -4.2% |
| 2002 Q1 | 57.18 Thousand CAD | 0.0% |
| 2002 FY | 208.86 Thousand CAD | 0.0% |
| 2002 Q4 | 44.45 Thousand CAD | -15.81% |
| 2002 Q3 | 52.79 Thousand CAD | -3.01% |
| 2002 Q2 | 54.43 Thousand CAD | -4.8% |
| 2001 FY | - CAD | -100.0% |
| 2001 Q2 | -545.79 Thousand CAD | -15.2% |
| 2001 Q3 | -472.8 Thousand CAD | 13.37% |
| 2001 Q1 | -473.79 Thousand CAD | -252.84% |
| 2001 Q4 | - CAD | 100.0% |
| 2000 Q1 | 1.00 CAD | 0.0% |
| 2000 Q2 | 1.00 CAD | 0.0% |
| 2000 Q3 | 1.00 CAD | 0.0% |
| 2000 Q4 | 309.99 Thousand CAD | 30999800.0% |
| 2000 FY | 310 Thousand CAD | 30999900.0% |
| 1999 FY | 1.00 CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Appili Therapeutics Inc. | 813.74 Thousand CAD | 149.524% |
| Eupraxia Pharmaceuticals Inc. | -209.91 Thousand CAD | -91.986% |
| Helix BioPharma Corp. | -14 Thousand CAD | -2778.571% |
| Microbix Biosystems Inc. | 7.48 Million CAD | 105.387% |
| Medicenna Therapeutics Corp. | -5000.00 CAD | -7960.0% |
| Satellos Bioscience Inc. | -8.81 Million CAD | 95.429% |
| Sernova Corp. | -445.55 Thousand CAD | 9.55% |